| scholarly article | Q13442814 |
| P50 | author | Michele T M Hu | Q64857486 |
| Mina Ryten | Q66724661 | ||
| P2093 | author name string | John Hardy | |
| Dennis W Dickson | |||
| Owen A Ross | |||
| Tamas Revesz | |||
| Thomas T Warner | |||
| Maryam Shoai | |||
| Huw R Morris | |||
| James B Rowe | |||
| Raffaele Ferrari | |||
| Günter U Höglinger | |||
| Clifton L Dalgard | |||
| Shunsuke Koga | |||
| Edwin Jabbari | |||
| Manuela M X Tan | |||
| Regina H Reynolds | |||
| Sonja W Scholz | |||
| Rebecca R Valentino | |||
| PSP Genetics Group | |||
| P2860 | cites work | Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS | Q21563317 |
| Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain | Q27303769 | ||
| Bayesian test for colocalisation between pairs of genetic association studies using summary statistics | Q28660129 | ||
| Genomewide association study of leprosy | Q28943354 | ||
| Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy | Q29417026 | ||
| Extending the use of GWAS data by combining data from different genetic platforms. | Q31168082 | ||
| Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial | Q34031302 | ||
| A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. | Q34118222 | ||
| Novel L284R MAPT mutation in a family with an autosomal dominant progressive supranuclear palsy syndrome | Q34804085 | ||
| LRRK2 inhibition attenuates microglial inflammatory responses | Q36493605 | ||
| Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes | Q36862751 | ||
| Brain homogenates from human tauopathies induce tau inclusions in mouse brain | Q36915421 | ||
| Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study | Q38667814 | ||
| NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases | Q38731672 | ||
| RNA splicing is a primary link between genetic variation and disease | Q38774701 | ||
| Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria | Q38807324 | ||
| Predictors of survival in progressive supranuclear palsy and multiple system atrophy: a systematic review and meta-analysis | Q39156848 | ||
| LRRK2 Promotes Tau Accumulation, Aggregation and Release. | Q40899192 | ||
| Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. | Q42324368 | ||
| In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy | Q42482808 | ||
| LRRK2 expression in normal and pathologic human brain and in human cell lines | Q45302732 | ||
| Functional mapping and annotation of genetic associations with FUMA. | Q47101248 | ||
| Study of LRRK2 variation in tauopathy: Progressive supranuclear palsy and corticobasal degeneration | Q47161677 | ||
| What is the evidence that tau pathology spreads through prion-like propagation? | Q47163825 | ||
| G2019S LRRK2 enhances the neuronal transmission of tau in the mouse brain. | Q47582501 | ||
| A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy | Q50479057 | ||
| [11C]PK11195 binding in Alzheimer disease and progressive supranuclear palsy. | Q53397590 | ||
| LRRK2 kinase in Parkinson's disease | Q54117350 | ||
| Peripheral immune system in aging and Alzheimer's disease | Q57039635 | ||
| Replication of progressive supranuclear palsy genome-wide association study identifies SLCO1A2 and DUSP10 as new susceptibility loci | Q57176763 | ||
| Distinctive features of lincRNA gene expression suggest widespread RNA-independent functions | Q57191758 | ||
| Joint genome-wide association study of progressive supranuclear palsy identifies novel susceptibility loci and genetic correlation to neurodegenerative diseases | Q57605565 | ||
| Variation at the TRIM11 locus modifies progressive supranuclear palsy phenotype | Q59133037 | ||
| Lrrk promotes tau neurotoxicity through dysregulation of actin and mitochondrial dynamics | Q60944606 | ||
| Long Non-coding RNAs Associated With Neurodegeneration-Linked Genes Are Reduced in Parkinson’s Disease Patients | Q64110558 | ||
| How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy | Q64774308 | ||
| Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum | Q90373014 | ||
| Comprehensive functional genomic resource and integrative model for the human brain | Q90462411 | ||
| Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies | Q91183320 | ||
| Silencing of long noncoding RNA RP11-476D10.1 enhances apoptosis and autophagy while inhibiting proliferation of papillary thyroid carcinoma cells via microRNA-138-5p-dependent inhibition of LRRK2 | Q92128512 | ||
| Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome | Q92146843 | ||
| Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial | Q92250841 | ||
| Genetic risk of Parkinson disease and progression:: An analysis of 13 longitudinal cohorts | Q92565228 | ||
| P4510 | describes a project that uses | genome-wide association study | Q1098876 |
| P921 | main subject | progressive supranuclear palsy | Q945930 |
| genome-wide association study | Q1098876 | ||
| P577 | publication date | 2020-12-17 | |
| P1433 | published in | Lancet Neurology | Q15755067 |
| P1476 | title | Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study |
| Q104504601 | LRRK2 and survival in progressive supranuclear palsy | cites work | P2860 |
Search more.